Dishman Carbogen Amcis Limited has informed the Exchange regarding a press release dated October 07, 2025, titled "PRESS RELEASE REGARDING COMPANY S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS AG, ANNOUNCED STRATEGIC ALLIANCE WITH CELONIC GROUP TO DELIVER FULLY INTEGRATED ADC DEVELOPMENT AND MANUFACTURING PLATFORM".
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dishman Carbogen Amcis Limited has announced that its Swiss wholly-owned subsidiary, Carbogen Amcis AG, has entered into a strategic alliance with Celonic Group, a Switzerland-based biologics contract development and manufacturing organization (CDMO). The partnership aims to create a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing platform, combining Carbogen Amcis's expertise in chemistry and linker-payload production with Celonic's biologics capabilities. ADCs are a rapidly growing class of targeted cancer therapies, and this alliance positions the combined platform to serve global biopharma clients across the full ADC value chain. No financial terms of the deal have been disclosed in the press release.
This is a positive strategic move that strengthens Dishman's positioning in the high-growth ADC CDMO segment, potentially unlocking new revenue streams and enhancing long-term growth prospects, though near-term financial impact remains unclear without deal terms.